Experimental CAR T-Cell therapy takes on progressive MS

NCT ID NCT06451159

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This early-stage trial tests a new treatment called KYV-101 for people with progressive multiple sclerosis (MS) that hasn't improved with standard treatments. KYV-101 is a CAR T-cell therapy made from a patient's own immune cells, designed to attack the cells causing inflammation in the brain and spinal cord. The study will enroll 10 participants to find the safest dose and see if the therapy can reach the central nervous system.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
KYV-101 (a CAR T-cell therapy made from your own immune cells)
What this could lead to
If it works, this could point toward a new treatment option for people with progressive multiple sclerosis who haven't responded to standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 10 participants, so it may not show clear benefit. There are also risks from the chemotherapy and the CAR T-cells themselves, including serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, San Francisco, Multiple Sclerosis Center

    San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.